incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Furthermore, the reaction conditions can be carefully controlled for desired product distribution, allowing for selective synthesis of desired cage structures. This dynamic character also enables template-directed synthesis, where specific molecular templates can guide the assembly process toward predetermined architectures. Both experimentally and computationally, various synthetic approaches have been developed to control cage formation and optimize yields. The choice of synthetic strategy significantly influences the final cage structure, purity, and scalability of the synthesis. Strategic synthetic approaches range from simple one-pot reactions to sophisticated template-directed methods, each offering distinct advantages.
Cape Town ⟷ Kimberley ⟷ Johannesburg: General freight Durban ⟷ Richards Bay: Coastal freight Johannesburg ⟷ Durban: General freight (SA's busiest intermodal freight corridor) Johannesburg ⟷ Gqeberha / Ngqura: Automotive exports and manufactured goods Johannesburg ⟷ Polokwane: Mining supplies, and agricultural and manufacturing freight Johannesburg ⟷ Richards Bay: General freight Johannesburg ⟷ KuGompo City: Automotive and general freight Johannesburg ⟷ Komatipoort: Cross-border freight to Mozambique and the rest of the SADC Johannesburg ⟷ Beitbridge: Cross-border freight into Zimbabwe Johannesburg ⟷ Mahikeng / Ramatlabama: Cross-border freight into Botswana As of 2026, Transnet Freight Rail moves 17% of South Africa's freight annually, including 100% of its export coal and iron ore. The company coordinates its rail freight services with other Transnet divisions, such as ports, pipelines, and engineering. With over 25,000 employees, Transnet Freight Rail generates over R14 billion in annual revenue. For its 2025/2026 financial year, Transnet expected to transport a total rail cargo volume of around 168 million tons, up around 5%, from 160.1 million tons the year before. Under the South African Government's rail restructuring plan, the goal is for Transnet to reach a transport capacity of 185 million tons, with a further 65 million tons transported by private operators, by 2030. This would make for a total South African cargo rail capacity of 250 million tons per year.
Murillo, Mario; Jesus Rey Avirama (September 1, 2003). Colombia and the United States: War, Terrorism and Destabilization. Seven Stories Press. ISBN 1-58322-606-0. Palacios, Marco (1995). Entre la legitimidad y la violencia: Colombia 1875–1994 (in Spanish). Norma. Pardo Rueda, Rafael (2004). La historia de las guerras (in Spanish). Ediciones B-Vergara. ISBN 958-97405-5-3. Hennecke, Angelika (2006). Zwischen Faszination und Gewalt : Kolumbien—unser gemeinsamer Nenner: Reflexionen über das Verhältnis zwischen kultureller Identität, Kommunikation und Medien anhand der diskursanalytischen Untersuchung einer kolumbianischen Werbekampagne (in German). Frankfurt am Main: Peter Lang. ISBN 3-631-54930-X. Pizarro Leongómez, Eduardo (1991). Las Farc: de la autodefensa a la combinación de todas las formas de lucha. Universidad Nacional. Tirado Mejía, Alvaro, ed. (1989). Nueva historia de Colombia. Planeta. Journals and periodicals
Male progeny prove Flora's unfertilized eggs were haploid (n) and doubled their chromosomes later to become diploid (2n) (by being fertilized by a polar body, or by chromosome duplication without cell division), rather than by her laying diploid eggs by one of the meiosis reduction-divisions in her ovaries failing. When a female Komodo dragon (with ZW sex chromosomes) reproduces in this manner, she provides her progeny with only one chromosome from each of her pairs of chromosomes, including only one of her two sex chromosomes. This single set of chromosomes is duplicated in the egg, which develops parthenogenetically. Eggs receiving a Z chromosome become ZZ (male); those receiving a W chromosome become WW and fail to develop, meaning that only males are produced by parthenogenesis in this species. It has been hypothesised that this reproductive adaptation allows a single female to enter an isolated ecological niche (such as an island) and by parthenogenesis produce male offspring, thereby establishing a sexually reproducing population (via reproduction with her offspring that can result in both male and female young). Despite the advantages of such an adaptation, zoos are cautioned that parthenogenesis may be detrimental to genetic diversity.
Sources: en.wikipedia.org
Many exiled Poles could not return to the country for which they had fought because they belonged to political groups incompatible with the new communist regimes, or because they originated from areas of pre-war eastern Poland that were incorporated into the Soviet Union (see Polish population transfers (1944–1946)). Some were deterred from returning simply on the strength of warnings that anyone who had served in military units in the West would be endangered. Many Poles were pursued, arrested, tortured and imprisoned by the Soviet authorities for belonging to the Home Army or other formations (see Anti-communist resistance in Poland (1944–1946)), or were persecuted because they had fought on the Western front.
=== United States === Similar to the law of Canada, the U.S. law (27 CFR 5.148) says that tequila must be "made in Mexico, in compliance with the laws and regulations of Mexico governing the manufacture of Tequila for consumption in that country."
=== Electrocardiogram === Electrocardiography (ECG/EKG in German vernacular. Elektrokardiogram) monitors electrical activity of the heart, primarily as recorded from the skin surface. A 12 lead recording, recording the electrical activity in three planes, anterior, posterior, and lateral is the most commonly used form. The ECG allows observation of the heart electrical activity by visualizing waveform beat origin (typically from the sinoatrial or SA node) following down the bundle of HIS and ultimately stimulating the ventricles to contract forcing blood through the body. Much can be learned by observing the QRS morphology (named for the respective portions of the polarization/repolarization waveform of the wave, P,Q,R,S,T wave). Rhythm abnormalities can also be visualized as in slow heart rate bradycardia, or fast heart rate tachycardia.
Sources: en.wikipedia.org
=== Phase 2 === ASP-8062 – GABAB receptor positive allosteric modulator – alcoholism BP-1.3656B (BP-1.3656; BP1.3656B; BP13656) – histamine H3 receptor antagonist – alcoholism BP-1.4979 (BP-1.4979; BP-14979; BP14979) – dopamine D3 receptor partial agonist – smoking withdrawal Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – smoking withdrawal Buprenorphine sublingual ethanol-free (CHF-6563; CHF6563) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone (naloxone/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Bupropion/dextromethorphan (bupropion/DXM; Auvelity; AXS-05) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist, CYP2D6 inhibitor) and dextromethorphan (DXM) (NMDA receptor antagonist, serotonin reuptake inhibitor, sigma receptor agonist, other actions) – smoking withdrawal Bupropion/naltrexone (Contrave; CX-101; Mysimba; naltrexone/bupropion; NB32) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist) and naltrexone (opioid receptor antagonist) – smoking withdrawal Cannabidiol (CBD; A-1002-N5S; Nantheia) – cannabinoid/various actions – opioid-related disorders, smoking withdrawal Cannabidiol (CBD; Epidiolex; Epidyolex; Epidiolexa; GW-42003; GWP-42003; GWP-42003-P; JZP-926) – cannabinoid/various actions – heroin-related disorders, opioid-related disorders Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – smoking withdrawal Cocaine esterase (RBP-8000; TNX-1300) – enzyme replacement – cocaine-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – alcoholism Devextinetug (anti-methamphetamine chimeric monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb) – immunomodulator (monocloncal antibody against methamphetamine) – substance-related disorders F-652 (IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; rhIL-22 dimer) – interleukin, immunoglobulin Fc fragment, recombinant fusion protein, anti-inflammatory, hepatoprotectant – alcoholism and alcoholic hepatitis Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor, toll-like receptor 4 (TLR4) antagonist – alcoholism, opioid-related disorders, substance-related disorders Liraglutide (LATIN-T1D; NN-2211; NN-9211; NN-8022; NNC-90-1170; Saxenda; Victoza) – glucagon-like peptide-1 (GLP-1) receptor agonist – smoking withdrawal Lixosicone (AEF-0117; AEF0117) – biased cannabinoid CB1 receptor negative allosteric modulator (pregnenolone derivative) – substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – alcoholism Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist – alcoholism Mebufotenin benzoate (5-MeO-DMT; BPL-002; BPL-003) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – cocaine-related disorders Midomafetamine (MDMA) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, entactogen – alcoholism Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – alcoholism Miricorilant (CORT-118335) – glucocorticoid and mineralocorticoid receptor antagonist – alcoholism Nadolol (INV-102; INV102) – non-selective beta blocker (β1- and β2 adrenergic receptor agonist) – smoking withdrawal Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate glycine-gated NMDA receptor agonist – cocaine-related disorders NNC0194-0499 (NN-9500; NN-9499; NNC-0194-0499) – fibroblast growth factor (FGF) receptor agonist – substance-related disorders NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – cocaine-related disorders OMS-405 (OMS405) – PPARγ agonist – opioid-related disorders, smoking withdrawal Pemvidutide (ALT-801- Altimmune; SP-1373; VPD-107) – glucagon-like peptide-1 (GLP-1) receptor agonists, glucagon receptor agonist – alcoholism Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Selonabant (ANEB-001; V-24343) – cannabinoid CB1 receptor antagonist – substance-related disorders Sunobinop (IMB-115; IT-1315; RSC117957; S-117957; V-117957) – nociceptin receptor agonist – alcoholism TA-CD (TA-CD; TA-CD09) – immunostimulant (cocaine vaccine) – cocaine-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – alcoholism Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – opioid-related disorders
=== Isolation === Muscimol can be extracted from the flesh of the Amanita muscaria by treatment with boiling water, followed by rapid cooling, and further treatment with a basic resin. This is washed with water, and eluted with acetic acid using column chromatography. The eluate is freeze dried, dissolved in water, and passed down a column of cellulose phosphate. A subsequent elution with ammonium hydroxide and recrystallization from alcohol results in pure muscimol. In instances where pure muscimol is not required, such as recreational or spiritual use, a crude extract is often prepared by simmering dried Amanita muscaria in water for 30 minutes.
Chlorpheniramine is an antihistamine that helps to relieve allergic disorders due to cold, hay fever, itchy skin, insect bites and stings. Chlorpromazine is a tranquilizer that sedates without inducing sleep. It is used to relieve anxiety, excitement, restlessness or even mental disorder. Ephedrine and phenylephrine, as amine hydrochlorides, are used as decongestants. Amphetamine, methamphetamine, and methcathinone are psychostimulant amines that are listed as controlled substances by the US DEA. Thioridazine, an antipsychotic drug, is an amine which is believed to exhibit its antipsychotic effects, in part, due to its effects on other amines. Amitriptyline, imipramine, lofepramine and clomipramine are tricyclic antidepressants and tertiary amines. Nortriptyline, desipramine, and amoxapine are tricyclic antidepressants and secondary amines. (The tricyclics are grouped by the nature of the final amino group on the side chain.) Substituted tryptamines and phenethylamines are key basic structures for a large variety of psychedelic drugs. Opiate analgesics such as morphine, codeine, and heroin are tertiary amines.
IR4: Infrared detector for composition and concentration measurements in polyolefins for gel permeation chromatography (GPC/SEC), HPLC, TREF, etc. IR5: an infrared detector for highly demanding applications in Polymer Char instruments such as GPC-IR, HPLC, CFC and other separation techniques. Part of the techniques and instruments were developed with Petrochemical companies and Research Institutes from United States, Belgium, Finland, Germany and Japan. The company supplies in over 35 countries around the globe Analytical Services for Polymer characterization.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.